CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.10 +2.42%

+$0.10 today

Market cap
$257.29M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.19M

Average 0.10M

CAMP EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

CAMP4 Therapeutics CorporationNASDAQ: CAMP

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -$0.32, compared with -$0.64 a year earlier. Trailing-twelve-month EPS (Basic) was -$2.27.

Context

  • EPS (Basic) grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 7 analysts of -$1.32 (+50.3%) for the fiscal year ending Dec 2026, a step up from the +0.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.32+59.0% QoQ
Last fiscal yearDec 2025
-$2.65+0.4% YoY
LTMMar 2026
-$2.27+19.2% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+50.0%+65.9%+15.9 pp
1 year+0.4%+50.3%+49.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(2.65) USD
Year-over-year change
+0.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How CAMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +19.2% is the 5th highest of 9, against a peer median of +22.7%.
CAMP Competitors
EPS (Basic) for CAMP and competitors
Company Period LTM YoY 3-year CAGR
VXRTVaxart, Inc.LTM Mar 2026$0.14 USD+147.7%—
HYFTMindWalk Holdings Corp.LTM Jan 2026-CA$0.29 CAD+81.9%—
ATYRaTyr Pharma, Inc.LTM Mar 2026-$0.73 USD+9.9%—
BMEABiomea Fusion, Inc.LTM Mar 2026-$0.89 USD+75.0%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026-$1.49 USD-313.9%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$1.65 USD+33.2%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026-$2 USD+9.9%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$2.05 USD+12.2%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026-$2.27 USD+19.2%—
Peer median (excluding CAMP) —+22.7%—

Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Feb 2022
FY2022
Feb 2023
FY2023
Nov 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue295.84M0350K652K3.5M
Cost of Revenue173.95M0001.64M
Gross Profit121.89M(947K)350K652K1.86M
Gross Margin41.2%—100.0%100.0%53.1%
Research & Development28.44M34.77M40.62M38.82M38.2M
Selling, General & Admin100.9M10.23M11.61M14.92M17.36M
Operating Expenses134.76M45M52.23M53.74M53.92M
Depreciation & Amortization22.8M878K1.68M1.7M1.64M
EBITDA7.49M(44.12M)(50.2M)(51.39M)(50.42M)
EBITDA Margin2.5%—-14343.1%-7882.2%-1441.5%
Operating Income(15.31M)(45M)(51.88M)(53.09M)(52.06M)
Operating Margin-5.2%—-14822.6%-8142.3%-1488.3%
Interest Income002.81M1.33M2.17M
Interest Expense15.32M6.26M000
Other Income / Expenses(14.75M)809K2.59M1.3M(28.34M)
Income Before Tax(30.06M)(44.19M)(49.29M)(51.79M)(80.4M)
Pre-Tax Margin-10.2%—-14083.1%-7943.4%-2298.5%
Income Tax Expense1.09M0000
Net Income(31.15M)(44.19M)(49.29M)(51.79M)(80.4M)
Net Margin-10.5%—-14083.1%-7943.4%-2298.5%
EPS (Basic)(0.88)(0.90)(4.07)(2.66)(2.65)
EPS (Diluted)(0.88)(0.90)(4.07)(2.66)(2.65)
Weighted Avg Shares35.25M36.1M12.12M19.51M30.38M
Weighted Avg Shares (Diluted)35.25M36.13M12.12M19.51M30.38M

CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Intrinsic Alpha fair value

Locked

Current Price

$4.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.